Mualliflar

  • Miraxmedova X.T., Raximova M.R.

##semicolon##

ревматоидный артрит, биомаркеры, Anti-CarP, VEGF.

##submission.citations##

1. Almutairi K et al. Epidemiology and classification criteria of rheumatoid arthritis: A review. Cureus.2021;13(1):e12549. https://doi.org/10.7759/cureus.12549

2. Angelotti F et al. Biomarkers and pathogenesis in rheu- matoid arthritis: Role of angiogenesis and hypoxia. 2021; 2021: 6672723. https://doi.org/10.1155/2021/6672723

3. Kim YJ et al. Clinical significance of VEGF as a biomarker in rheumatoid arthritis patients. Diagnostics.2023;13(9):1653. https://doi.org/10.3390/diagnostics13091653

4. Kleyer A, Schett G. Arthritis and bone loss: A clinical review. Bone.2018;117:227-34. https://doi.org/10.1016/j. bone.2018.09.007

5. Li H et al. IL-17A and TNF-α synergy in rheumatoid ar- thritis pathogenesis. Sign Transduct Target Ther.2024;9(1):34. https://doi.org/10.1038/s41392-023-01331-9

6. Navarro-Millἀn I et al. Biomarkers in rheumatoid ar- thritis: A review on the pathogenesis and clinical utility. Curr Rheumatol Rep.2019;21(6):30. https://doi.org/10.1007/ s11926-019-0831-5

7. Shi J et al. Anti-CarP antibodies as predictors of joint damage in rheumatoid arthritis. Rheumatology International, (2023). 43, 801–809. https://doi.org/10.1007/s00296-023- 05251-2

8. Smolen JS et al. Rheumatoid arthritis. Lancet. 2020; 396 (10246): 1681-94. https://doi.org/10.1016/S0140-6736(20)32323-5

9. Watanabe A et al. Predictive value of anti-CarP and ACPA antibodies in early RA: A longitudinal cohort study. BMC Mus- culoskeletal Dis.2022;23(1):527. https://doi.org/10.1186/ s12891-022-05555-w

10. Willemze A et al. The ACPA response in RA: Understanding its importance and diagnostic value. Front Immunol. 2019;10:113. https://doi.org/10.3389/fimmu.2019.01113